Literature DB >> 1728750

Therapeutic use of type F botulinum toxin.

C L Ludlow, M Hallett, K Rhew, R Cole, T Shimizu, G Sakaguchi, J A Bagley, G M Schulz, S G Yin, J Koda.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1728750     DOI： 10.1056/NEJM199201303260516

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

Authors:  R Eleopra; V Tugnoli; R Quatrale; O Rossetto; C Montecucco; D Dressler
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

2.  Differences in neuromuscular junctions of laryngeal and limb muscles in rats.

Authors:  Xin Feng; Tan Zhang; Evelyn Ralston; Christy L Ludlow
Journal:  Laryngoscope       Date:  2012-02-28       Impact factor: 3.325

3.  Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.

Authors:  M K Houser; G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

4.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Costs of treating dystonias and hemifacial spasm with botulinum toxin A.

Authors:  R C Dodel; A Kirchner; R Koehne-Volland; G Künig; A Ceballos-Baumann; M Naumann; A Brashear; H P Richter; T D Szucs; W H Oertel
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 6.  Cervical dystonia pathophysiology and treatment options.

Authors:  M Velickovic; R Benabou; M F Brin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

8.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 9.  Botulinum toxin in clinical practice.

Authors:  A J Hughes
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

10.  Stabilization of botulinum toxin type A during lyophilization.

Authors:  M C Goodnough; E A Johnson
Journal:  Appl Environ Microbiol       Date:  1992-10       Impact factor: 4.792
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.